Seeking Alpha

Isis Pharmaceuticals (ISIS +1.8%) has earned a $6M payment from AstraZeneca (AZN +0.8%) as part...

Isis Pharmaceuticals (ISIS +1.8%) has earned a $6M payment from AstraZeneca (AZN +0.8%) as part of their partnership to develop antisense therapeutics to treat cancer. In the six months since the collaboration was announced, Isis and AztraZeneca have decided to develop the ISIS-ARRx compound for use in treating prostate cancer, and initiated two clinical studies for ISIS-STAT3Rx in patients with advanced lymphomas and liver cancer. (previous) (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs